Icatibant Dosing for Hereditary Angioedema
The recommended dose of icatibant is 30 mg administered subcutaneously in the abdominal area for adults, with weight-based dosing for pediatric patients: 10 mg (12-25 kg), 15 mg (26-40 kg), 20 mg (41-50 kg), 25 mg (51-65 kg), and 30 mg (>65 kg). 1
Adult Dosing
Standard dose: 30 mg subcutaneous injection in the abdominal area 1
Repeat dosing parameters:
- Additional doses may be given at minimum 6-hour intervals if response is inadequate or symptoms recur 1
- Maximum 3 doses in any 24-hour period 1
- The majority of attacks respond to a single dose in real-world practice 2
Administration technique:
- Inject over at least 30 seconds 1
- Patients can self-administer after appropriate training 1
- Early self-administration leads to faster symptom resolution and shorter attack duration 2
Pediatric Dosing
Weight band-based regimen (approved for ages ≥2 years): 3, 4
- 12-25 kg: 10 mg
- 26-40 kg: 15 mg
- 41-50 kg: 20 mg
- 51-65 kg: 25 mg
- >65 kg: 30 mg (adult dose)
This weight-banded approach was validated through population pharmacokinetic modeling and achieves exposure levels comparable to the 0.4 mg/kg dosing used in clinical trials 3. The FDA label currently indicates use in adults ≥18 years 1, though clinical trial data supports efficacy and safety in children as young as 2 years 4, 5.
Clinical Efficacy Timeline
Expected response: Median time to onset of symptom relief is approximately 1.0-2.5 hours across all age groups 6, 7, 4. In pediatric patients specifically, the median time was 1.0 hour for both prepubertal children and adolescents 4. Time to minimum symptoms typically occurs within 2 hours 5.
Critical Safety Considerations
Laryngeal attacks require special management: Even after icatibant administration, patients with laryngeal involvement must seek immediate medical attention at a facility capable of airway management, as airway obstruction can progress despite treatment 1. This is non-negotiable.
Common adverse effects:
- Injection-site reactions occur in 97% of patients but are typically mild-to-moderate and resolve within 6 hours 1, 4
- Most common reactions include erythema, swelling, pain, and pruritus at injection site 1
- Other reactions (pyrexia, transaminase elevation, dizziness) occur in <4% of patients 1
Practical Implementation
The subcutaneous prefilled syringe formulation (10 mg/mL concentration, 3 mL total volume) enables rapid self-administration or caregiver administration in pediatric patients 4, 8. This is particularly valuable given that early treatment—facilitated by home administration—significantly improves outcomes by reducing attack duration and severity 2.
Important caveat: While icatibant demonstrated statistical superiority over tranexamic acid (2.0 vs 12.0 hours to symptom relief, P<0.001) 6, the placebo-controlled FAST-1 trial showed only numerical benefit (2.5 vs 4.6 hours, P=0.14) 6, 7, likely due to early rescue medication use obscuring treatment effect 7. However, real-world registry data from 549 patients and 5,995 attacks confirms effectiveness comparable to clinical trial efficacy 2.
The evidence strongly supports icatibant as a first-line on-demand treatment option across all age groups, with the advantage of subcutaneous self-administration enabling immediate treatment at attack onset—a critical factor in optimizing outcomes 9, 2.